PSP Research LLC Makes New $534,000 Investment in Royalty Pharma PLC $RPRX

PSP Research LLC bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 13,826 shares of the biopharmaceutical company’s stock, valued at approximately $534,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RPRX. Smartleaf Asset Management LLC boosted its stake in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Private Trust Co. NA boosted its stake in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 288 shares during the last quarter. Larson Financial Group LLC boosted its stake in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 306 shares during the last quarter. Fifth Third Bancorp boosted its stake in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 362 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Royalty Pharma during the 3rd quarter worth $100,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.7%

Shares of RPRX stock opened at $52.41 on Wednesday. The company’s 50-day moving average price is $48.58 and its 200-day moving average price is $43.61. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a market cap of $30.18 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 1.43 and a beta of 0.40. Royalty Pharma PLC has a twelve month low of $32.15 and a twelve month high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $631.00 million for the quarter, compared to analysts’ expectations of $881.69 million. As a group, equities analysts predict that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. Royalty Pharma’s dividend payout ratio is 63.95%.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04. Following the sale, the executive vice president directly owned 31,881 shares in the company, valued at $1,691,605.86. This represents a 30.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 155,893 shares of company stock worth $7,512,360 over the last three months. Company insiders own 18.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on RPRX shares. Citigroup lifted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley boosted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $53.71.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.